Detoxification treatments for opiate dependent adolescents.

CONCLUSIONS: It is difficult to draw conclusions on the basis of two trials with few participants. Furthermore, the two studies included did not consider the efficacy of methadone that is still the most frequent drug utilised for the treatment of opioid withdrawal. One possible reason for the lack of evidence could be the difficulty in conducting trials with young people due to practical and ethical reasons.
PMID: 24777492 [PubMed – as supplied by publisher] (Source: Cochrane Database of Systematic Reviews)

Detoxification treatments for opiate dependent adolescents.

CONCLUSIONS: It is difficult to draw conclusions on the basis of two trials with few participants. Furthermore, the two studies included did not consider the efficacy of methadone that is still the most frequent drug utilised for the treatment of opioid withdrawal. One possible reason for the lack of evidence could be the difficulty in conducting trials with young people due to practical and ethical reasons.
PMID: 24777492 [PubMed – as supplied by publisher] (Source: Cochrane Database of Systematic Reviews)

MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.

Behavioural treatment combined with buprenorphine does not reduce opioid use compared with buprenorphine alone

Question Question: In the treatment of opioid dependence, does the addition of behavioural treatment to buprenorphine reduce opioid use compared with buprenorphine alone? Patients: In total, 202 people meeting Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revised (DSM-IV-TR) criteria for opioid dependence. Participants had to have good general medical and psychiatric health, no sensitivity to buprenorphine or naloxone, and no dependence on alcohol, benzodiazepines or any other drug. Setting: Outpatient clinical research centre in Los Angeles, California, USA. Intervention: In total, 16 weeks of buprenorphine with medical management plus either cognitive behavioural therapy (CBT, n=53), contingency management (CM, n=49), both CBT and CM (CBT+CM, n=49) or no b…

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Behavioural treatment combined with buprenorphine does not reduce opioid use compared with buprenorphine alone

Question Question: In the treatment of opioid dependence, does the addition of behavioural treatment to buprenorphine reduce opioid use compared with buprenorphine alone? Patients: In total, 202 people meeting Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revised (DSM-IV-TR) criteria for opioid dependence. Participants had to have good general medical and psychiatric health, no sensitivity to buprenorphine or naloxone, and no dependence on alcohol, benzodiazepines or any other drug. Setting: Outpatient clinical research centre in Los Angeles, California, USA. Intervention: In total, 16 weeks of buprenorphine with medical management plus either cognitive behavioural therapy (CBT, n=53), contingency management (CM, n=49), both CBT and CM (CBT+CM, n=49) or no b…

MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.

Respiratory effects of buprenorphine/naloxone alone and in combination with diazepam in naive and tolerant rats.

In conclusion, differences in respiratory effects between BUP/NLX and BUP are only significant in combination with DZP, with increased depression in naive rats but reduced depression in in BUP-tolerant rats. However, BUP/NLX benefits in humans remain to be determined.
PMID: 24769261 [PubMed – as supplied by publisher] (Source: Toxicology Letters)

Respiratory effects of buprenorphine/naloxone alone and in combination with diazepam in naive and tolerant rats.

In conclusion, differences in respiratory effects between BUP/NLX and BUP are only significant in combination with DZP, with increased depression in naive rats but reduced depression in in BUP-tolerant rats. However, BUP/NLX benefits in humans remain to be determined.
PMID: 24769261 [PubMed – as supplied by publisher] (Source: Toxicology Letters)

Abuse and diversion of buprenorphine sublingual tablets and film – Lavonas EJ, Severtson SG, Martinez EM, Bucher-Bartelson B, Le Lait MC, Green JL, Murrelle LE, Cicero TJ, Kurtz SP, Rosenblum A, Surratt HL, Dart RC.

Buprenorphine abuse is common worldwide. Rates of abuse and diversion of three sublingual buprenorphine formulations (single ingredient tablets; naloxone combination tablets and film) were compared. Data were obtained from the Researched Abuse, Diversion, … (Source: SafetyLit: All (Unduplicated))

Abuse and diversion of buprenorphine sublingual tablets and film – Lavonas EJ, Severtson SG, Martinez EM, Bucher-Bartelson B, Le Lait MC, Green JL, Murrelle LE, Cicero TJ, Kurtz SP, Rosenblum A, Surratt HL, Dart RC.

Buprenorphine abuse is common worldwide. Rates of abuse and diversion of three sublingual buprenorphine formulations (single ingredient tablets; naloxone combination tablets and film) were compared. Data were obtained from the Researched Abuse, Diversion, … (Source: SafetyLit: All (Unduplicated))

MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.